A Phase 2A Multicentre, Randomised, Double Blind, Placebo-Controlled, Parallel-Group Safety and Tolerability Study of PQ912 in Subjects With Early Alzheimer's Disease (SAPHIR)

NCT02389413 Phase 2 COMPLETED

The aim of this study is to evaluate the safety, tolerability and preliminary efficacy of PQ912 in subjects with Mild Cognitive Impairment (MCI) due to Alzheimers Disease (AD) or mild dementia due to AD.

Details

Lead sponsor	Vivoryon Therapeutics N.V.
Phase	Phase 2
Status	COMPLETED
Enrolment	120
Start date	2015-03
Completion	2017-04

Conditions

• Alzheimer's Disease

Interventions

• PQ912 oral
• Placebo

Primary outcomes

• Frequency of adverse events and serious adverse events (the study is a Phase II safety trial) — 12 weeks

Countries

Belgium, Finland, France, Germany, Netherlands, Spain, Sweden